A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumoursMichael Warso, Tapas K. Das Gupta, Linda R. Bressler et al.|British Journal of Cancer|2013Cited by 182